| Name | Title | Contact Details |
|---|
Ellipse Technologies is a privately held medical device company that is dedicated to the design, development and successful commercialization of non-invasively adjustable, remote controlled implants for a broad spectrum of spinal and orthopedic applications. As part of its product portfolio, the company has developed remote controlled distraction systems using magnets which may eliminate the need for additional surgeries for adjustment. The initial revolutionary products restore proper anatomic position and alignment of the spine and correct limb length discrepancies of the femur and tibia. Ellipse is located in Irvine, California.
CORE Ingredients and Packaging is a Opa Locka, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BioMedcom Consultants Inc is a Varennes, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Vinsanity Shred is a brand with many different products and online personal training and meal plans that are guaranteed to get you your dream body.
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.